about
Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.Are Australian clinicians monitoring medication adherence in hematological cancer survivors? Two cross-sectional studies.High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.Enrollment of patients to clinical trials in haematological cancer in New South Wales: current status, perceived barriers and opportunities for improvement.Consensus guidelines for 'rainy day' autologous stem cell harvests in New South Wales.Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.Results of a double blind placebo controlled study of ondansetron as an antiemetic during total body irradiation in patients undergoing bone marrow transplantation.Bone marrow transplantation--the Marsden experience.'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosisHow do allogeneic bone marrow transplants cure leukaemia? The role of graft versus host diseaseHuman recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trialNo increase in relapse in patients with myeloid leukaemias receiving rhGM-CSF after allogeneic bone marrow transplantationTreatment of acute graft versus host disease with a murine monoclonal antibody to the IL-2 receptorFeasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemiaA novel factor V null mutation at Arg 506 causes a false positive Factor V Leiden resultAcute Myeloid Leukaemia Following Matched Allogeneic Bone Marrow Transplantation for T-Cell Lymphoblastic LymphomaRaccoon eyes in systemic light chain amyloidosisThe delayed diagnosis of myeloproliferative neoplasms is common and results in a high incidence of potentially preventable thrombotic complicationsA multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons
P50
Q33440617-17D20635-5555-4816-9040-2A58377F47DBQ33795058-2BCD3369-24B7-4857-A840-5C34C7325239Q35747603-0739254C-26A7-4BB0-948A-4243694EEDA8Q37030719-B41D65A6-088B-42E8-916F-C7CF578F6D19Q37394310-7105D065-EBDE-4464-8C82-C35FFD5DEF2AQ40107848-0973BD68-5320-4417-B3C4-7D6FCEAAD845Q40190940-77ECD738-4A56-4771-BE76-70A8F6D6E8CEQ45136294-4BB8BB2D-A6B3-44E3-B963-36F8542A9010Q47579996-AFF62257-C8E7-4E25-8187-1A081C1997A2Q48205014-2EFB5CEE-1406-42F0-A85F-31677B8B1CD3Q53505510-EBD50592-CCCF-4A84-8D2C-64B00FF92299Q61774659-A8F14BAF-756F-4C24-BFDA-155A8697C427Q67955816-25283BAA-5B82-491D-800B-B81A2F094CE3Q68162558-5E583C94-E2C9-4988-9B0C-8C1F131E8F79Q68202192-A95983D6-C216-4EAD-AE17-4768F7DA9820Q68250545-67A65341-CD38-4EF6-B91F-DF056B96BFFBQ72750830-FAFB0DF5-B778-4791-840C-9C11C6C3D927Q73013610-536045AE-8297-48D7-B3B7-C4EAAF0F40BEQ88009755-56A5B2D9-A206-47F7-B9F3-D25B9B97D152Q88032104-48B87466-BB3E-4939-A1ED-88D523B169BAQ91819988-14E56EFE-F2A6-4749-B1EC-A6FAED48E04BQ91948223-25CC1327-6173-4CDF-88A3-9F9F077F48FB
P50
description
researcher ORCID ID = 0000-0002-4314-0877
@en
wetenschapper
@nl
name
Campbell Tiley
@ast
Campbell Tiley
@en
Campbell Tiley
@es
Campbell Tiley
@nl
type
label
Campbell Tiley
@ast
Campbell Tiley
@en
Campbell Tiley
@es
Campbell Tiley
@nl
prefLabel
Campbell Tiley
@ast
Campbell Tiley
@en
Campbell Tiley
@es
Campbell Tiley
@nl
P31
P496
0000-0002-4314-0877